Summary.-The combination of hyperthermia and the hypoxic cell radiosensitizer Ro-07-0582 has been investigated on the EMT6 tumour implanted into the legs of BALB/c mice. Treatments at a drug dose of 1 mg/g over a range of waterbath temperatures from 37 to 45°C are described. The surviving clonogenic fraction following treatment was assayed in vitro. Measurements of intra-tumour temperature have been made, and shown to be better correlated with the cytocidal effect on the tumour than the waterbath temperature.
IT is thought likely that the presence of hypoxic cells in tumours may contribute towards the failure of cure by radiotherapy. Recent work on drugs which increase the radiosensitivity of hypoxic cells has been directed at this problem (reviewed by Adams, 1973) . The nitroimidazoles appear to be a particularly promising group of agents, and of these the 2-nitroimidazole (1-(2-nitroimidazol-l-yl)-3-methoxy-2-propanol), designated Ro-07-0582, has been most extensively investigated, as reviewed by Adams and Fowler (1976) . Evidence is also now accumulating that these imidazole compounds may be selectively cytotoxic for hypoxic cells (Sutherland, 1974; Hall and RoizinTowle, 1975; Mohindra and Rauth, 1976; Foster et al., 1976; Brown, 1975; Sutherland et al., 1976) .
There is also much current interest in the possible role of hyperthermia as a method for cancer therapy. Treatment by temperatures in excess of 41 50C may produce cell killing, as reviewed by Suit and Shwayder (1974) , Bleehen (1976), Thrall et al. (1976) and Bronk (1976) . Synergistic effects have been described when hyperthermia is combined with chemotherapy (Hahn, Braun and Har-Kedar, 1975 ) and reviewed by Har-Kedar and Bleehen (1976) , and Dickson and Suzangar (1976) . Evidence has also been presented that cell killing by hyperthermia may be enhanced by hypoxia (Gerweck, Gillette and Dewey, 1974; Kim, Kim and Hahn, 1975a) and that a significant reduction in oxygen enhancement ratio (OER) may be obtained when irradiated cells are subsequently treated for 2 h at 42°C (Kim, Kim and Hahn, 1] 
975b).
In this paper we present data obtained during experiments investigating the combination of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse mammary tumour treated in vivo. Brief preliminary details have already been reported (Bleehen, Honess and Morgan, 1976) .
MATERIALS AND METHODS
Aninmals.-Male BALB/c mice between 10 and 14 weeks of age, and weighing 20 to 25 g were used.
Tumours.-The EMT6 tumour was first described by Rockwell, Kallman and Fajardo (1972 used. The probes were inserted into the flank of the animal above the water level and passed, subcutaneously, down to the tumour, in an attempt to avoid major errors due to heat conduction along the probe. The end of the probe which contained the thermistor bead was routinely sited as near as possible to the centre of the tumour. Some measurements were carried out to investigate temperature variation across the tumour. The temperature of the tumours was found to rise rapidly during the first 5 min to within 0-5°C of the final temperature. In some animals it continued to rise slowly over the subsequent 5 min. The rectal temperature never rose above 39°C. The temperature given as " intra-tumour temperature " in all cases refers to the final peak temperature.
The presence of the probe in the tumour did cause some bleeding, which was exacerbated at higher temperatures. It should be noted that the tumour masses recorded include the blood and clots where these occurred, and that in general the higher the waterbath temperature, the more hyperaemic the tumour appeared to be. However, for the 440C waterbath data, the distribution of points is such that there is no evidence for a significant difference. The same is true for lower waterbath temperatures. Fig. 2 shows composite results for the series of experiments where intra-tumour measurements were made with SF plotted against intra-tumour temperature. Fewer experiments have been performed with these intra-tumour measurements than the total number of experiments in this series. The data demonstrate that the toxic effect of Ro-07-0582 is marked at intra-tumour temperatures of more than 42*5°C, whereas at intra-tumour tempera- In vitro cytotoxicity to metronidazole (2-methyl-5-nitroimidazole-1-ethanol) has been reported by Sutherland (1974) and Mohindra and Rauth (1976) and, in vivo, by Inch and McCredie (1975) and Foster et al. (1976) . In vitro hypoxic cell cytotoxicity of Ro-07-0582 has been reported by Sutherland et al. (1976) and Hall and Roizin-Towle (1975) .
RESULTS

Fig
In vivo cytotoxicity of Ro-07-0582 has been demonstrated by Denekamp and Harris (1975) We have not demonstrated any significant cytotoxicity of Ro-07-0582 on the EMT6 tumour at 37°C, even though the hypoxic cell fraction of this tumour is around 30°/% (Rockwell and Kallman, 1973; Bleehen, Har-Kedar and Watson, unpub.) . There are various possible explanations for this apparent anomaly. If all the hypoxic cells were killed by an acute exposure to the drug, the resulting expected average surviving fraction of 0 7 would be difficult to detect with precision because of the considerable variation between tumours. Certainly any smaller degree of cell killing would not be seen, as a result of this variation. Our technique for a solid tumour differs from that of most of the previously mentioned authors investigating the cytotoxicity of the hypoxic cell sensitizers, in that tumour cells are removed from the animal immediately after the completion of the 1-h exposure in the water bath. The surviving fraction is then assayed in vitro. Only Brown (1975) has used this in vivoin vitro method. He reports that the cytotoxicity of Ro-07-0582 that he observed with the EMT6 tumour does not occur if the tumours are removed from the animals within 1 h of injection. This then raises a further possible explanation for the apparent anomaly, which may relate to the change with time of the concentration of the drug in the serum and in the hypoxic cells of the tumour. We do not have any data on this matter, but do observe peak radiosensitization of the tumour in both airbreathing and the hypoxic state within 30 min of administration of the drug (Bleehen et at., unpub. (1976) reported that the half-life of Ro-07-0582 in mice is around 1-1 h. So it may be that exposure for several hours, even though the serum level is declining, is necessary to achieve detectable cytotoxicity. The in vitro work of Hall and Roizin-Towle (1975) demonstrated such a time-dependent cytotoxicity with Ro-07-0582.
A further observation should be made concerning the estimate of hypoxic cell fraction of around 30% in the EMT6 tumour (Rockwell and Kallman, 1973; Bleehen et al., unpub.) . These estimates were based on the radiation treatment of tumours in vivo followed by assay of cell survival in vitro. McNally (1975) has shown, with Sarcoma F in CBA mice, that this technique may considerably overestimate the hypoxic cell fraction, relative to that obtained from growth delay curves. Such an analysis for the EMT6 tumour is not really possible. Growth delay estimations with the EMT6 tumour do demonstrate a greater sensitivity to radiation than might be expected on the basis of cell-survival curves (Rockwell and Kallman, 1973) . However, this may be related to the immunogenicity of the tumour, and makes invalid a comparison of the data similar to that of McNally (1975) .
The effect of hyperthermia over the range of temperatures described in this paper is consistent with the observations of numerous previous authors, as reviewed by Suit and Shwayder (1974) and HarKedar and Bleehen (1976) . The heat sensitivity of EMT6 tumour cells in vitro has been reported by Hahn et al. (1975) , Kal, Hatfield and Hahn (1975) , Kal and Hahn (1976) . In vivo hyperthermia studies with this tumour have been carried out by Hahn et al. (1975) , Hahn (1976), Miller, Veomett and Gerner (1976) . The cytotoxic effect of hyperthermic treatment is dependent on both temperature and exposure time. We have not investigated this aspect extensively in the present work, but selected a fixed duration of 1 h hyperthermia over a waterbath temperature range which spans a measurable cell survival. The highest temperatures of 44-450C result in some normal tissue damage in the limbs when animals are allowed to survive. The maximum skin reaction is similar to that seen in animals treated with 2100 rad breathing air at room temperature, but with a more evanescent time course. This reaction is compatible with long-term survival of the animal. However, temperatures above 45°C result in unacceptable morbidity.
A temperature gradient between tumour and waterbath for the EMT6 tumour in legs has been observed by other workers Kal and Hahn, 1976) . This inhomogeneity of temperature has obvious experimental disadvantages.
The presence of this gradient across the tumour may also be of significance because of the possibility of a differential sensitivity to heat at these sites. It is known that a difference in pulse-labelling index (LI) may be observed across tumours. This has been related to changes in nutritional and oxygenation status (Hermens and Barendsen, 1969) . A similar difference in LI is seen for the EMT6 tumour (Rockwell et al., 1972; Rockwell, Frindel and Tubiana, 1976) and confirmed in our laboratory (Watson, unpub.) .
It is also possible that there may be differences in the magnitude of the hypoxic cell fraction in our tumour over the range of sizes investigated, as reported with other tumours (Suit and Maeda, 1967; Peters, 1976) .
A gradient of hypoxic cells across the tumour may be of significance in this series of experiments when (1) this results in differences in plating efficiency of cells viable in terms of trypan blue exclusion, (2) if there is a concentration gradient of Ro-07-0582, (3) or when there is a significant temperature gradient.
We do not believe that the first two possibilities are of significance. We have not observed any difference in the plating efficiency of tumour cells from the peri-phery or centre of tumours at 37°C. Ro-07-0582 is freely diffusible and only slowly metabolized (Adams and Fowler, 1976) and full radiosensitization by the drug of hypoxic cells in EMT6 tumours (in the flank) has been reported (Brown, 1975; Bleehen et al., unpub.) .
The presence of a temperature gradient across the tumour is of more significance. Small changes in temperature over the range 42-45°C may produce large changes in cell killing. It has also been reported that hypoxic cells are more sensitive to killing by heat than in oxic cells (Gerweck et at., 1974; Kim et at., 1975a) . The surviving fractions assayed in this paper will therefore be a product of the temperature and hypoxic cell gradients.
Our observation that the combination of hyperthermia and Ro-07-0582 may produce a considerable cell killing in vivo has been confirmed by us with the EMT6 cell line in monolayer cultures (unpub. data) and by Stratford and Adams (1977) with the Chinese hamster V79-379A cell line in spinner cultures. Enhanced cytotoxicity with other cancer chemotherapeutic agents and hyperthermia has been reported reviews by Har-Kedar and Dickson and Suzangar, 1976) . This may be due to increased permeability of the cells to drugs, or to inhibition of repair of potentially lethal damage . Stratford and Adams (1977) have discussed their results with Ro-07-0582 in terms of Arrhenius parameters, and have concluded that the toxicity is a consequence of cellular metabolism of the drug, and that increased temperatures result in its increased metabolism. We do not have enough data from our in vivo model to be able to make such an analysis.
It is also difficult to make a meaningful quantitative comparison between the in vitro and in vivo situation because of the uncertainty about the relative proportion of oxic and hypoxic cells in vivo. Our results indicate cell killing considerably in excess of that to be expected from previous estimates of the hypoxic cell fraction in the EMT6 tumour, which have been made under similar conditions of anaesthesia but at room temperature (Rockwell and Kallman, 1973; Bleehen et al., unpub.) . This could indicate increased cytotoxicity of the drug in our system on oxygenated as well as hypoxic cells at the higher temperatures. Changes in cellular 02 consumption occur with rise in tumour temperature (Bronk, 1976) . This may then increase the hypoxic cell fraction. The present experiments do not distinguish between these possibilities. We would expect that the peak serum concentration of the drug after a 1 mg/g i.p. dose should be about 5 mM (Adams and Fowler, 1976) . This concentration of drug may affect division of aerobic V79-379A cells in vitro, but does not affect their viability (Stratford and Adams, 1977) . Our preliminary data with EMT6 cells in vitro also confirm this observation.
Before the clinical significance of our observations can be assessed, it will be important to know whether or not there is repair of the observed cell damage if the tumours are left intact in vivo. Recovery from potentially lethal damage has been described for X-radiation (Little, et al., 1973) and some cancer chemotherapeutic agents Twentyman and Bleehen, 1975) . However, Hahn et al. (1975) have reported that hyperthermia will inhibit the repair of bleomycin damage. The clinical use of the combination of heat and hypoxic-cell sensitizers will also depend on an improvement in the therapeutic gain when the effect on normal tissues is considered. We are currently investigating these problems in our experimental system. We wish to thank Dr Carey Smithen of Roche Products Ltd for supplies of Ro-07-0582 and Dr G. E. Adams for useful discussions. We are also grateful to N. M. Maclaren for statistical advice.
